LTGO

Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

Peers: VRTX XENE LXRX TRVI PRAX AXSM PCRX HRTX SUPN NBIX

| Held by: VTI VXF SCHA SCHB VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	942.61M
Enterprise Value	542.39M
Income	-
Sales	-
Book/sh	5.94
Cash/sh	6.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.39
P/C	2.35
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	29.11
Current Ratio	29.11
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.53
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	22.64%
Sales Q/Q	-
Earnings	Nov 05 BMO
EPS/Sales Surpr.	12.08% -

Insider Own	55.55%
Insider Trans	0.77%
Inst Own	16.59%
Inst Trans	17.40%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.17%
SMA50	-18.29%
SMA200	-22.68%
Trades

Shs Outstand	66.30M
Shs Float	29.47M
Short Float	3.19%
Short Ratio	3.19
Short Interest	0.94M
52W High	25.93 -45.17%
52W Low	10.24 38.84%
Volatility	17.77% 11.64%
ATR (14)	1.63
RSI (14)	45.36
Beta	-
Rel Volume	0.35
Avg Volume	295.08K
Volume	64,258

Perf Week	1.26%
Perf Month	-9.50%
Perf Quarter	-29.13%
Perf Half Y	-
Perf YTD	-32.30%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	52.25
Prev Close	13.33
Price	14.22
Change %	6.66%

Consensus

Strong Buy

Avg. Price Target

$52.25

Implied Upside

+267.5%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 01, 2026	Initiated	LLeerink Partners	Outperform	$36	+153.2%
Sep 01, 2026	Initiated	JJefferies	Buy	$50	+251.7%
Sep 01, 2026	Initiated	GGuggenheim	Buy	$50	+251.7%
Sep 01, 2026	Initiated	GGoldman	Buy	$73	+413.5%

Nov-05-26 06:47AM	Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -7.34%
06:45AM	Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth (GlobeNewswire)
Nov-03-26 04:05PM	Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +7.85%
Sep-03-26 04:05PM	Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Capital Management V,	10% Owner	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:21 PM
Tananbaum James B.	Director	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:00 PM

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.

Chief Medical OfficerDr. Neil Kumar Singla M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

Latigo Biotherapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.